Leaders in Lupus Community Highlight List of Panelists for National Policy Summit
Leaders from government, the biotechnology and pharmaceutical industry, and the lupus medical and research community will headline the Lupus Foundation of America’s National Policy Summit: Advocacy In Action on June 26-27 in Washington, D.C.
This diverse and highly respected group of panelists also includes people living with lupus who will bring their perspectives to each of the panel discussions. The speakers, announced today, will lead three interactive and educational panel discussions.
More than 200 lupus advocates are expected for the two-day Summit. They'll have the opportunity to directly engage with these lupus thought leaders, and learn about the latest developments in lupus research and education.
The first panel, Accelerating Lupus Research, will be moderated by our own Susan Manzi, M.D., Medical Director for the LFA. The panel will cover the barriers facing lupus research and drug development and what the lupus community is doing to overcome those barriers. This session will also highlight how people with lupus and their families can contribute to overcoming the challenges in advancing lupus research.
Jill P. Buyon, M.D. and Director, Division of Rheumatology, Department of Medicine at New York University will moderate the second panel, The Role of Federal Agencies in Lupus Research, Education and Awareness. This session will update the lupus community on the latest initiatives underway through key government programs, and clearly demonstrate how our advocacy efforts make a difference. This panel will underscore the importance of the Congressional meetings that will take place on day two of the Summit.
Below, you will find the complete list of participants serving on these two panels.
Get Exclusive Access to These Leaders in the Lupus Community
- Moderator: Susan Manzi, M.D., M.P.H., Chair, Department of Medicine, Allegheny Health Network
- Monique Gore-Massey, Lupus Advocate
- Robert H. Carter, M.D., Deputy Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Michele M. Oshman, Director, Federal Advocacy and Alliance Development, Eli Lilly and Company
- Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, Food and Drug Administration
- Moderator: Jill P. Buyon, M.D., Director, Division of Rheumatology, Department of Medicine, New York University
- Wendy Rodgers, Lupus Advocate
- Margaret J. Kaniewski, MPH, Project Officer, Centers for Disease Control
- Evelyn Lewis, M.D., American Academy of Family Physicians
- Joseph M. Ahearn, M.D., Director, Asthma Allergy and Autoimmunity Institute, Director, Lupus Center of Excellence
Stay tuned for details of the third panel, The Promising Pipeline in Lupus Drug Development, which will include representatives from the pharmaceutical industry engaged in lupus drug development.
The exciting speakers we are securing will update Summit attendees about their efforts to bring new treatments to people living with lupus.